BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

53 related articles for article (PubMed ID: 20071984)

  • 1. Hematopoietic stem cell transplantation in Zagreb: the first 40 years.
    Labar B
    Croat Med J; 2023 Apr; 64(2):123-134. PubMed ID: 37131314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study.
    El Cheikh J; Bidaoui G; Atoui A; Terro K; Sharrouf L; Zahreddine A; Moukalled N; Abou Dalle I; Bazarbachi A; Mohty M; Dulery R
    Bone Marrow Transplant; 2023 Jun; 58(6):667-672. PubMed ID: 36914730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduced intensity vs. myeloablative conditioning with fludarabine and PK-guided busulfan in allogeneic stem cell transplantation for patients with AML/MDS.
    Alatrash G; Kidwell KM; Thall PF; Di Stasi A; Chen J; Zope M; Crain AK; Champlin RE; Popat U; Shpall EJ; Jones RB; Andersson BS
    Bone Marrow Transplant; 2019 Aug; 54(8):1245-1253. PubMed ID: 30532055
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease.
    Hosoya H; Levine J; Abt P; Henry D; Porter DL; Gill S
    Blood Adv; 2018 Mar; 2(5):575-585. PubMed ID: 29535106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation.
    Majhail NS; Farnia SH; Carpenter PA; Champlin RE; Crawford S; Marks DI; Omel JL; Orchard PJ; Palmer J; Saber W; Savani BN; Veys PA; Bredeson CN; Giralt SA; LeMaistre CF
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):1863-1869. PubMed ID: 26256941
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pushing the envelope-nonmyeloablative and reduced intensity preparative regimens for allogeneic hematopoietic transplantation.
    Pingali SR; Champlin RE
    Bone Marrow Transplant; 2015 Sep; 50(9):1157-67. PubMed ID: 25985053
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies.
    Ricci MJ; Medin JA; Foley RS
    World J Stem Cells; 2014 Sep; 6(4):380-90. PubMed ID: 25258660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease.
    El-Jawahri A; Pidala J; Inamoto Y; Chai X; Khera N; Wood WA; Cutler C; Arora M; Carpenter PA; Palmer J; Flowers M; Weisdorf D; Pavletic S; Jaglowski S; Jagasia M; Lee SJ; Chen YB
    Biol Blood Marrow Transplant; 2014 Sep; 20(9):1341-8. PubMed ID: 24813171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Failure of hypomethylating agent-based therapy in myelodysplastic syndromes.
    Kadia TM; Jabbour E; Kantarjian H
    Semin Oncol; 2011 Oct; 38(5):682-92. PubMed ID: 21943675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantation.
    Oran B; Wagner JE; DeFor TE; Weisdorf DJ; Brunstein CG
    Biol Blood Marrow Transplant; 2011 Sep; 17(9):1327-34. PubMed ID: 21232621
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning for allogeneic stem cell transplantation in patients with chronic myeloid leukemia is associated with better overall survival but inferior disease-free survival when compared with myeloablative conditioning - a retrospective study of the Czech National Hematopoietic Stem Cell Transplantation Registry.
    Faber E; Koza V; Vitek A; Mayer J; Sedlacek P; Zak P; Zapletalova J; Benesova K; Krejcova H; Steinerova K; Maresova I; Cetkovsky P;
    Neoplasma; 2007; 54(5):443-6. PubMed ID: 17688375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allogeneic stem cell transplantation for myelodysplastic syndrome.
    Barrett AJ; Savani BN
    Semin Hematol; 2008 Jan; 45(1):49-59. PubMed ID: 18179969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced-intensity conditioning allogeneic stem cell transplantation for older adults: is it the standard of care?
    McClune BL; Weisdorf DJ
    Curr Opin Hematol; 2010 Mar; 17(2):133-8. PubMed ID: 20071984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced intensity conditioning for allogeneic hematopoietic stem cell transplantation in myelodysplastic syndromes and acute myelogenous leukemia.
    Valcárcel D; Martino R
    Curr Opin Oncol; 2007 Nov; 19(6):660-6. PubMed ID: 17906468
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 3.